tiprankstipranks

Biogen, Eisai confirm CHMP positive opinion for lecanemab

Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti-Abeta monoclonal antibody lecanemab, adopted in November 2024. Following CHMP’s reaffirmation, after having considered the additional information requested by the European Commission, the EC will resume the decision-making process for lecanemab’s marketing authorization.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue